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Introduction
In adult mammals the kidney is the major source of the hormone erythropoietin, which stimulates red blood cell production. As a result, patients with chronic renal failure are often anemic due, at least partly, to inadequate erythropoietin (EPO) production. Treatment with pharmacological doses of recombinant erythropoietin is expensive and has recently been linked to increased morbidity and mortality due to cardiovascular events 1, 2 . Some patients also become refractory to recombinant erythropoietin over time due to a variety of host factors including antibodies against the recombinant protein itself or altered iron homeostasis secondary to humoral factors such as hepcidin 3, 4 .
Transcription of the erythropoietin gene (EPO) is controlled by the heterodimeric transcription factor HIF (Hypoxia-Inducible Factor) and hence intimately linked to oxygen delivery to the kidneys, which are normally borderline hypoxic at rest and poised to respond to further decrements in oxygen delivery 5 . HIF consists of an unstable alpha subunit (such as HIF1α or HIF2α) and a stable beta subunit (such as HIF1β, which is also called ARNT1) 6 . In the presence of oxygen HIFα becomes prolyl hydroxylated by members of the EglN (also called PHD) family of 2-oxoglutarate-dependent dioxygenases, leading to its polyubiquitination and proteasomal degradation 6 . As oxygen levels fall EglN activity is diminished, leading to HIF stabilization and activation.
There are three EglN family members although EglN1 (also called PHD2) is the primary regulator of HIF, with EglN2 (PHD1) and EglN3 (PHD3) playing compensatory roles under certain circumstances 6 . The analysis of families, as well as of genetically
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From engineered mice, with hereditary polycythemia (excess red blood cells) implicate EglN1 and HIF2α as the critical regulators of erythropoietin, and hence red blood cell production, in adults 7, 8 .
During fetal life the liver, rather than the kidney, is the major source of erythropoietin. Moreover non-renal tissues, most likely including the liver, can contribute to erythropoietin production in anephric, hypoxemic, adults [9] [10] [11] . In this regard,
we recently showed that erythropoietin production was markedly induced in adult hepatocytes lacking all three EglN family members, supporting the idea that the liver can contribute to circulating erythropoietin levels in the setting of chronic kidney disease 12 .
Orally available EglN inhibitors can stimulate red blood cell production in preclinical models and are currently being clinically tested as potential treatments for anemia, including anemia linked to chronic kidney disease 11, 13, 14 . It is not yet known, however, whether chronic, systemic, HIF activation will lead to untoward side-effects in man. Moreover, it is possible that some EglN inhibitors will have off-target effects, such as inhibiting other enzymes that are structurally related to the EglN family members. In an effort to achieve a more targeted approach, we exploited the ability of lipid nanoparticles to deliver siRNAs specifically to the liver as a means of inactivating hepatic EglN activity.
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Materials/Methods

Cre-Lox Experiments
EglN1 flox/flox (EglN f/f
) and HIF1α-Luc reporter mice were described previously 13, 15 .
The EglN2 -/-and EglN3 -/-mice were a gift of Regeneron Pharmaceuticals, Inc.
(Tarrytown, NY). All the EglN strains were backcrossed to C57BL/6 mice at least six times. 4 Table S1 for sequences.
siRNA Formulation in Lipid Nanoparticles
The LNPs were prepared with an ionizable lipid, disteroylphosphatidyl choline, cholesterol, and PEG-DMG using a spontaneous vesicle formation procedure as previously described at a component molar ratio of ~50/10/38.5/1.5 17, 18 . The final lipid:siRNA ratio was ~12:1. The particle size of LNPs was determined by dynamic light scattering (Zetasizer Nana ZS; Malvern) and the mean diameter was in the range of 40-70nm for all LNPs used in these studies. The siRNA entrapment efficiency was determined by Ribogreen assay to be >95%. injection at a volume of 0.01 ml/g. For blood draws animals were anesthetized by isofluorane inhalation and blood was collected into serum separator tubes or EDTAcontaining tubes by retroorbital bleeds. In some cases tail pricks were used for small amounts of blood to monitor hematocrit levels using capillary tubes. For 5/6 nephrectomy experiments animals underwent the procedure at Charles River laboratories. One kidney was removed and the animal was allowed to recover 1 week before 2/3 of the second kidney was removed. Over 2-3 weeks the hematocrit levels were monitored every 5 days to determine anemia progression. Treatment began when hematocrit levels reached approximately 30%. Animals were dosed every 4 days for a total of 3 doses and sacrificed 4 days post the final dose for hematology and tissue mRNA analysis. For rat anemia experiments a single IP injection of PG-APS (a polymer derived from group A streptococci) was used to induce arthritis [19] [20] [21] . After an acute phase of inflammation the rats were bled weekly for CBC analysis, with chronic anemia (hematocrit < 35%)
developing by day 21. Beginning at day 21 animals were dosed with siRNA weekly for 3 total doses with serum and hematology parameters measured bi-weekly throughout the treatment period. Animals were sacrificed at day 37 and tissues harvested to measure target mRNA levels.
Serum Epo ELISA and Hematology
At various time points or immediately prior to animal sacrifice blood was collected and processed to serum (Microcontainer serum separator tubes, Becton Dickinson). Serum Epo was measured using a mouse/rat Erythropoietin ELISA kit (R&D Systems) according to the manufacturer's instructions. Standard complete blood counts (CBC)
were monitored using an Advia120 system (Bayer).
Tissue mRNA Quantification
After animals were sacrificed tissues were snap frozen in liquid nitrogen and ground into powders. Tissue lysates were prepared in lysis buffer containing Proteinase K (Epicenter) and levels of siRNA target mRNA determined relative to GAPDH or Beta-Actin housekeeping genes using a branched DNA assay according to the manufacturer's instructions (Quantigene reagent system, Panomics).
5'RACE assay
Total RNA was isolated from sorted cells using Trizol (Invitrogen) and RNAeasy mini columns (Qiagen). Roughly 2µg of RNA was used for 5'RACE similar to the Generacer kit (Invitrogen) protocol. The oligonucleotide adaptor was ligated directly to total RNA using T4 RNA ligase (2U) for 1 h at 37°C. The ligation mixture was reverse transcribed using the EglN1, EglN2, and EglN3 gene-specific oligos (Table S2) round PCR EglN oligos paired with the adaptor oligo in individual reactions in a 50µl total reaction volume. A second round of nested PCR was performed with 3µl of the first reaction for 25 cycles where T m =55°C using the respective nested oligos and the nested adaptor oligo. PCR products were examined by gel electrophoresis, and the total PCR reaction was cloned into pCR4-TOPO vector for sequencing (Invitrogen).
Statistical Analysis
Data shown are mean +/-standard deviations. Results were analyzed for statistical significance using one or two way ANOVAs where appropriate followed by Bonferroni 
Results
Acute EglN Inactivation Promotes Hepatic Epo production
We recently showed that hepatic Epo production was preserved in adult mice in which all three EglN family members were genetically disrupted, either in the germline or during late embryogenesis, but not in mice that retained at least one of the three family members 12 . Moreover, we showed that acute inactivation of EglN1 in adult mice lacking Figure 1) . Moreover, hepatic Epo mRNA levels were persistently elevated in livers lacking all three EgN paralogs whereas they reverted toward normal in mice that retained EglN2 and EglN3 (supplemental Figure   1 ). Therefore acute inactivation of EglN1 stimulates hepatic Epo production but this effect is transient in nature because of compensation by EglN2 and/or EglN3.
Simultaneous inactivation of all three EglN family members appears to be necessary and sufficient for sustained, high level, hepatic Epo production in genetically engineered models of EglN inactivation Consistent with this, pan-EglN small molecule inhibitors induce Epo/EPO production in anephric mice and in patients with chronic renal failure 11, 13, 14 . These agents, however, might theoretically affect other 2-oxoglutarate-dependent dioxygenases and affect tissues other than the liver. In an effort to achieve a more targeted approach,
we exploited the fact that many currently available siRNA delivery methods preferentially target the liver 17, 23, 24 . Significant improvements in potency with the newest generation of lipid nanoparticles (LNPs) have enabled robust knockdown of multiple genes simultaneously 18, 25 .
We first designed and validated siRNAs that are specific for mouse EglN1, EglN2, or EglN3, which were then administered by tail vein injection, either alone or in combinations using LNPs ( Figure 1A ). These siRNAs achieved dose dependent In keeping with our earlier results using Cre-Lox technology, inactivation of EglN1 alone led to a modest induction of circulating Epo (supplemental Figures 3 and 4) , without a sustained increase in hepatic Epo mRNA production (supplemental Figures 3 and 4) , whereas hepatic Epo mRNA ( Figure 1C ) and circulating Epo ( Figure 1D ) were dramatically increased in mice that received LNPs containing siRNAs against all three EglN family members. The induction of circulating Epo in this setting was detectable out to 2 weeks after siRNA administration ( Figure 1F ) and was associated with a sustained increase in red blood cell production ( Figure 1E,G) . Similar results were obtained with mixtures of three LNPs that contained single siRNAs against either
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EglN3 (data not shown). Hematocrit values began to fall approximately 3 weeks after the last dose of EglN siRNA (approximately 2 weeks after the peak in serum Epo) with kinetics compatible with a normal murine red blood cell half-life of about 10 days 27, 28 ( Figure 1F, G) . Liver histology and serum transaminase and bilirubin levels remained normal in mice that were treated weekly with the EglN siRNA nanoparticles for 1 month prior to necropsy, despite robust induction of HIF1α and HIF2α (supplemental Figure 5 and data not shown).
Non-invasive Pharmacodynamic Imaging of EglN siRNA
We previously showed that EglN activity can be monitored non-invasively in mice that ubiquitously express a HIF1α-luciferase fusion protein that contains a region of HIF1α that is sufficient to be hydroxylated by EglN and subsequently ubiquitinated by the pVHL ubiquitin ligase complex 13 . As expected, administration of the EglN siRNA mix to these mice decreased hepatic, but not renal, EglN activity as determined by increased photon emission in the region of the liver, but not kidneys, following luciferin administration ( Figure 2A ). Branched DNA analysis confirmed that EglN1, EglN2, and EglN3 mRNAs were decreased in the liver ( Figure 2B ), but not in the other organs examined, such as the kidney ( Figure 2C and supplemental Figure 6 and data not shown), and was associated with an increase hepatic, but not renal, Epo mRNA production ( Figure 2D ). Epo mRNA induction was undetectable in spleen or any other tissue examined further supporting the hepatic origin of the serum Epo rise (data not shown).
The EglN mRNA silencing primarily in liver is consistent with the known biodistribution of this class of lipid nanoparticles 17, 18 . EglN knockdown did not increase HIFα mRNA
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5' RACE analysis using liver samples from mice treated with EglN siRNA in
LNPs was done to confirm that the decrease in EglN mRNA levels was occurring by an
RNAi mechanism and not due to off-target effects. The EglN transcripts 1, 2, 3 were cleaved at the predicted site recognized by the corresponding siRNA sequence. After PCR amplification the products run on a gel were of the expected size for each EglN gene and sequencing confirmed the predicted siRNA recognition sites ( Figure 2E -F). We also observed an increase in hepatic photon emission in HIF1α-luciferase reporter mice treated with EglN1 siRNA alone, but not EglN2 or EglN3 siRNA alone, consistent with EglN1 being the primary regulator of HIF1α under normal conditions (supplemental Figure 8 ).
EglN siRNA Ameliorates Anemia in Preclinical Models
We next asked if EglN siRNA could be used to treat anemia in the setting of chronic renal failure. Toward this end mice were subjected to 5/6 nephrectomy, which is a widely used model for anemia linked to renal failure, or sham operations ( Figure 3A and 3G). The mice undergoing nephrectomy, upon developing anemia, were then randomized to receive phosphate buffered saline (PBS), control siRNA (luciferase siRNA), siRNAs (singly or in combination) targeting EglN1, both EglN1 and EglN2, or all three EglN family members. Knockdown of the intended EglN mRNAs was again documented by branched chain DNA analysis (Fig 3B-D) . In keeping with the data described above, inactivation of EglN1 led to a modest increase in red blood cell
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From production, which was markedly accentuated by coinactivation of EglN2 ( Figure 3H and I). The maximal erythropoietic response, however, was observed after treatment with siRNA targeting all 3 EglN paralogs ( Figure 3E, H and I ). EglN inactivation in this model also decreased hepcidin mRNA levels, consistent with earlier studies using chemical hydroxylase inhibitors (Figure 3F ) 29, 30 . Control of hepcidin by HIF appears to be multifactorial and complex, potentially involving cell-autonomous effects of hepatic HIF on hepcidin transcription as well as indirect effects stemming from enhanced erythropoiesis 29, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] .
Chronic inflammation can lead to anemia due, at least partly, to increased levels of hepcidin and altered iron trafficking (anemia of chronic disease) 41, 42 . Rats with experimental arthritis induced by a polymer of a streptococcal antigen (PG-APS) have been used as a model for the anemia linked to inflammation [19] [20] [21] . In the 5/6 nephrectomy model combined inactivation of EglN1 and EglN2 was sufficient to induce a brisk erythropoietic response ( Figure 3E ,H,I) and we were able to identify siRNAs that can effectively target rat EglN1 and EglN2 ( Figure 4A-C) . Treatment of anemic PG-APS rats with mixtures of siRNAs targeting both EglN1 and EglN2 decreased their hepcidin levels ( Figure 4D ), increased hepatic Epo mRNA levels ( Figure 4E ) and corrected their anemia ( Figure 4F and G). Since treatment with EglN siRNA downregulated hepcidin, which is a master regulator of iron homeostasis, we also examined a number of serum iron parameters. We saw trends of improvement in serum iron, ferritin, and transferrin saturation (TSAT) without significant effects on TIBC or UIBC (supplemental Figure 9 ).
Discussion
These studies suggest that systemically administered siRNAs targeting the EglN family would ameliorate anemias characterized by an absolute or relative deficiency of erythropoietin, such as anemias linked to chronic kidney disease or inflammation, in man.
This approach would allow the body to produce native erythropoietin, thereby obviating the need for recombinant versions of this hormone. Moreover other hepatic changes induced by EglN inhibition, such as decreased production of hepcidin, might enhance the effectiveness of endogenous erythropoietin and thereby lower the circulating erythropoietin levels needed to promote red blood cell production. This might be desirable if some of the cardiovascular complications of chronic erythropoietin production are more tightly linked to circulating erythropoietin levels, especially when supraphysiological, than to red blood cell mass per se 43 .
Small molecule EglN inhibitors that interfere with the ability of these enzymes to utilize 2-oxoglutarate, iron, or both, are currently in clinical development and are capable of stimulating erythropoietin production in the setting of chronic renal failure 11, 13, 14 .
These agents have several theoretical advantages over recombinant erythropoietin, in addition to those outlined above for EglN siRNA, including an ability to activate many HIF-responsive genes that play roles in iron metabolism and erythropoiesis in tissues such as the liver, intestine, and bone marrow. As such, one might argue that EglN inhibitors will more faithfully mimic the normal adaptation to hypoxemia than do pharmacological doses of erythropoietin. On the other hand, it is possible that some small molecule EglN inhibitors will have off-target toxicities related to inhibition of other 2-oxoglutarate-dependent dioxygenases. Moreover, hypothetical concerns have been Null alleles for targets of interest are often used to predict the consequences of inhibiting those targets in patients with drug-like small molecules. Germline null alleles, however, can be impractical or misleading if their protein products also play roles during embryological development. This problem can be circumvented by the use of conditional alleles that can be inactivated using, for example, Cre-Lox technology. The loss of alleles produced by such recombination events, however, typically mimic complete and irreversible target loss whereas most successful drugs are useful because they induce partial, reversible, target inhibition that can be titrated to achieve their desired effects. Based on these considerations one might predict that siRNAs, in addition to being potential therapeutics in their own right, will become increasingly important tools to model potential drug effects in vivo, especially if they can be delivered systemically.
Perhaps related to these considerations, mice engineered to have sustained, highlevel, hepatic HIF activation develop fatty liver (steatosis) associated with impaired fatty acid oxidation 26, [46] [47] [48] [49] [50] . 
